Citius Oncology (CTOR) Consolidated Net Income (2023 - 2026)

Citius Oncology (CTOR) has reported Consolidated Net Income for 4 consecutive years, with -$8.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Consolidated Net Income fell 66.18% year-over-year to -$8.9 million in Q2 2026; TTM through Jun 2026 was -$46.1 million, a 35.08% decrease from a year earlier, with the FY2025 full-year figure at -$24.8 million, down 17.08% from the prior year.
• Consolidated Net Income was -$8.9 million for Q2 2026 at Citius Oncology, up from -$26.6 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at -$147922.0 in Q1 2023 and troughed at -$26.6 million in Q1 2026.
• A 4-year average of -$7.4 million and a median of -$5.5 million in 2025 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income slumped 7083.92% in 2024 and surged 62.54% in 2025, its largest moves.
• Over 4 years, Consolidated Net Income stood at -$4.7 million in 2023, then plunged by 40.86% to -$6.7 million in 2024, then rose by 16.9% to -$5.5 million in 2025, then slumped by 61.25% to -$8.9 million in 2026.
• The last three Consolidated Net Income figures came in at -$8.9 million (Q2 2026), -$26.6 million (Q1 2026), and -$5.5 million (Q4 2025), per Business Quant data.